S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
Log in

Best Stocks Under $50.00 for 2021

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $50.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $50.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $50.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.


NGM Biopharmaceuticals logo

#1 - NGM Biopharmaceuticals

NASDAQ:NGM
Stock Price: $27.89 (+$0.10)
PE Ratio: -20.97
Market Cap: $1.92 billion
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $36.50 (30.9% Upside)
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Village Farms International logo

#2 - Village Farms International

NASDAQ:VFF
Stock Price: $12.93 (+$0.10)
PE Ratio: -258.55
Market Cap: $865.17 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $18.80 (45.4% Upside)
Village Farms International, Inc., together with its subsidiaries, produces, markets, and distributes greenhouse-grown tomatoes, bell peppers, and cucumbers in North America. It operates through three segments: Produce Business, Energy Business, and Cannabis and Hemp Business. The company also owns and operates a 7.0 megawatt power plant that generates and sells electricity to British Columbia Hydro and Power Authority; and produces and supplies cannabis products. It markets and distributes its products under the Village Farms brand name to retail supermarkets and fresh food distribution companies, as well as products produced under exclusive arrangements with other greenhouse producers. The company was formerly known as Village Farms Canada Inc. and changed its name to Village Farms International, Inc. in December 2009. Village Farms International, Inc. was founded in 1989 and is headquartered in Delta, Canada.
Ayr Strategies logo

#3 - Ayr Strategies

OTCMKTS:AYRWF
Stock Price: $29.17 (+$1.35)
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $38.75 (32.8% Upside)
Ayr Strategies Inc., a vertically-integrated cannabis multi-state operator, cultivates and manufactures branded cannabis products for distribution through its network of retail outlets and through third-party stores primarily in Massachusetts and Nevada. The company was incorporated in 2017 and is headquartered in New York, New York.
Tarsus Pharmaceuticals logo

#4 - Tarsus Pharmaceuticals

NASDAQ:TARS
Stock Price: $42.02 (+$1.10)
Market Cap: $853.85 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $37.25 (-11.4% Upside)
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.
Ameris Bancorp logo

#5 - Ameris Bancorp

NASDAQ:ABCB
Stock Price: $42.95 (-$1.72)
PE Ratio: 13.02
Market Cap: $2.98 billion
P/E Ratio: 13.0
Dividend Yield: 1.34 %
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $33.20 (-22.7% Upside)
Ameris Bancorp operates as the bank holding company for Ameris Bank that provides banking services to retail and commercial customers primarily in Georgia, Alabama, Florida, and South Carolina. The company operates through five segments: Banking Division, Retail Mortgage Division, Warehouse Lending Division, SBA Division, and Premium Finance Division. It offers commercial and retail checking, regular interest-bearing savings, money market, individual retirement, and certificates of deposit accounts. The company also provides commercial real estate, residential real estate mortgage, agricultural, and commercial and industrial loans; consumer loans, including motor vehicle, home improvement, and home equity loans, as well as loans secured by savings accounts and small unsecured personal credit lines; and municipal and commercial insurance premium finance loans. It operates 170 domestic banking offices and 31 mortgage and loan production offices. Ameris Bancorp was founded in 1971 and is headquartered in Atlanta, Georgia.
Telephone and Data Systems logo

#6 - Telephone and Data Systems

NYSE:TDS
Stock Price: $20.35 (-$0.50)
PE Ratio: 10.65
Market Cap: $4.36 billion
P/E Ratio: 10.7
Dividend Yield: 3.26 %
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $30.90 (51.8% Upside)
Telephone and Data Systems, Inc., a telecommunications company, provides communications services in the United States. It operates through three segments: U.S. Cellular, Wireline, and Cable. The company offers cellular services to postpaid and prepaid customers, including retail consumers, government entities, and business customers located in its service territories; national plans with voice, messaging, and data usage options; and advanced wireless solutions, such as machine-to-machine solution and software applications for various categories of monitor and control, business automation/operations, communication, and asset management. It also provides wireless devices comprising handsets, tablets, mobile hotspots, home phones, and routers; and accessories that include wireless essentials, which comprise cases, screen protectors, chargers, and memory cards, as well as various consumer electronics, such as headphones, smart speakers, wearables, and home automation products. In addition, the company offers wireline services to residential customers comprising broadband and digital television video services, as well as voice services, such as local and long-distance telephone, voice over Internet protocol (VoIP), find me follow me, collaboration, instant messaging, and other services; broadband, IP-based, and hosted voice and collaboration services to small- and medium-sized businesses; and wireline services to traditional interexchange and wireless carriers. Further, it provides business services, including data networking, Ethernet, broadband access, and VoIP services to small- and medium-sized businesses, as well as operates 262 retail stores and kiosks. The company offers its services to approximately 6 million connections. It sells its products through retail sales, direct sales, third-party retailers, and independent agents, as well as through website and telesales. The company was incorporated in 1968 and is headquartered in Chicago, Illinois.
Flagstar Bancorp logo

#7 - Flagstar Bancorp

NYSE:FBC
Stock Price: $47.18 (+$1.83)
PE Ratio: 6.12
Market Cap: $2.48 billion
P/E Ratio: 6.1
Dividend Yield: 0.44 %
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $46.60 (-1.2% Upside)
Flagstar Bancorp, Inc. operates as a savings and loan holding company for Flagstar Bank, FSB that provides commercial and consumer banking services to individuals and businesses in the United States. Its Community Banking segment offers various products, such as checking accounts, savings accounts, money market accounts, certificates of deposit, consumer and commercial loans, commercial real estate loans, equipment finance and leasing, home builder finance loans, and warehouse lines of credit. It also provides other financial services, including consumer and corporate card services, customized treasury management solutions, merchant services, and capital markets services, such as loan syndications, and investment and insurance products and services. This segment serves consumer, business, and mortgage lending customers through its branch banking, business and commercial banking, government banking, warehouse lending, and loans held-for-investment (LHFI) portfolio groups. The company's Mortgage Originations segment originates, acquires, and sells one-to-four family residential mortgage loans through mortgage branches, call centers, the Internet, and third party counterparties. Its Mortgage Servicing segment offers services and subservices mortgage loans; and the servicing of residential mortgages for its LHFI portfolio, as well as noninterest-bearing escrow services. As of December 31, 2019, the company provided banking services through 160 full service banking branches; and mortgages through a wholesale network of brokers and correspondents in 50 states, as well as 88 retail locations in 27 states. Flagstar Bancorp, Inc. was founded in 1987 and is headquartered in Troy, Michigan.
Bird Construction logo

#8 - Bird Construction

OTCMKTS:BIRDF
Stock Price: $6.91 (+$0.08)
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.40 (50.4% Upside)
Bird Construction Inc. operates as a general contractor in Canada. The company primarily focuses on projects in the industrial, commercial, and institutional sectors of the general contracting industry. It constructs industrial buildings; and performs civil construction operations, including site preparation, concrete foundations, metal and modular fabrication, mechanical process work, underground piping, and earthwork for clients primarily operating in the oil and gas, liquefied natural gas, mining, and nuclear sectors. The company also engages in the construction and renovation of shopping malls, big box stores, office buildings, hotels, and selected high rise condominiums and apartments; and the construction of hospitals, post-secondary education facilities, schools, prisons, courthouses, government buildings, and retirement and senior housing facilities, as well as environmental facilities, such as water and wastewater treatment centers, composting facilities, and biosolids treatment and management facilities. It serves clients in the commercial, institutional, retail, multi-tenant residential, industrial, mining, water and wastewater, energy, civil, light industrial, and renovation and restoration sectors. Bird Construction Inc. was founded in 1920 and is based in Mississauga, Canada.
Mirum Pharmaceuticals logo

#9 - Mirum Pharmaceuticals

NASDAQ:MIRM
Stock Price: $18.84 (+$0.26)
PE Ratio: -5.48
Market Cap: $484.51 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $40.60 (115.5% Upside)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.
Everi logo

#10 - Everi

NYSE:EVRI
Stock Price: $13.56 (-$0.19)
PE Ratio: -13.29
Market Cap: $1.17 billion
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.83 (9.4% Upside)
Everi Holdings Inc. provides entertainment and technology solutions for the casino, interactive, and gaming industries in the United States, Europe, Canada, the Caribbean, Central America, and Asia. It operates in two segments, Games and FinTech. The company offers local and wide-area progressive gaming products, such as classic mechanical reel games, video reel games, Empire 5527, Empire Flex, Empire DCX, Empire MPX, Core HDX, and the Texan HDX; TournEvent, a slot tournament terminal and system machine; and sells player terminals, licenses, back office systems, and other related equipment. It also provides cash access services, such as ATM cash withdrawals, POS debit card cash access transactions, and credit card cash access transactions; check verification and warranty services; CashClub, a software payments platform that provides gaming establishments with a personal computer workstation software user interface and point-of-sale terminal; fully integrated kiosks that provide multiple functions to the casino floor; and other integrated kiosk solutions. In addition, the company offers non-ATM terminals that perform authorizations for credit card cash access and POS debit card transactions; database services; and an online payment processing solution for gaming operators in states that offer intra-state and Internet-based gaming and lottery activities. Further, it provides Everi Compliance solutions to assist casino operators with meeting regulatory requirements; Central Credit, a gaming patron credit bureau service; JackpotXpress, a jackpot payout and tax form management platform; player loyalty platform; and EveriCares for socially conscious ticket redemption. The company was formerly known as Global Cash Access Holdings, Inc. and changed its name to Everi Holdings Inc. in August 2015. Everi Holdings Inc. was founded in 1998 and is headquartered in Las Vegas, Nevada.
Canfor logo

#11 - Canfor

OTCMKTS:CFPZF
Stock Price: $19.12 (+$0.96)
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $25.42 (32.9% Upside)
Canfor Corporation operates as an integrated forest products company in the United States, Canada, Europe, Asia, and internationally. It operates in two segments, Lumber, and Pulp and Paper. The company manufactures and sells softwood lumber, pulp and paper products, remanufactured lumber products, engineered wood products, and wood pellets, as well as produces green energy. It also offers wood chips, logs, and kraft paper; and produces and sells pulp and paper products, including northern bleached softwood kraft and bleached chemi-thermo mechanical pulp. The company's products are used in residential, commercial, and industrial construction. Canfor Corporation was founded in 1938 and is based in Vancouver, Canada.
Interfor logo

#12 - Interfor

OTCMKTS:IFSPF
Stock Price: $18.13
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $27.42 (51.2% Upside)
Interfor Corp. engages in the manufacture of wood products. It harvests and purchases logs which are sorted by species, size, and quality. Its products include appearance timbers, decking, framing, furniture, industial packaging, paneling, windows, and doors. The company was founded on May 6, 1963 and is headquartered in Vancouver, Canada.
89bio logo

#13 - 89bio

NASDAQ:ETNB
Stock Price: $20.69 (-$0.42)
PE Ratio: -4.10
Market Cap: $411.30 million
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $61.57 (197.6% Upside)
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Teranga Gold logo

#14 - Teranga Gold

OTCMKTS:TGCDF
Stock Price: $10.07 (-$0.03)
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $17.75 (76.3% Upside)
Teranga Gold Corporation engages in the exploration, development, production, and sale of gold in West Africa. The company's flagship project is the Sabodala gold mine covering an area of 291 square kilometers mine license and 629 square kilometers exploration land package located in the Republic of Senegal. The company was incorporated in 2010 and is headquartered in Toronto, Canada.
Northern Oil and Gas logo

#15 - Northern Oil and Gas

NYSEAMERICAN:NOG
Stock Price: $10.85 (-$0.72)
PE Ratio: -0.48
Market Cap: $497.48 million
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.75 (26.7% Upside)
Northern Oil and Gas, Inc., an independent energy company, engages in the acquisition, exploration, exploitation, development, and production of crude oil and natural gas properties in the United States. The company primarily holds interests in the Bakken and Three Forks formations in the Williston Basin of North Dakota and Montana. As of December 31, 2019, it owned working interests in 6,156 gross producing wells; and had proved reserves of 163.3 million barrels of oil equivalent. The company is based in Minnetonka, Minnesota.
Tourmaline Oil logo

#16 - Tourmaline Oil

OTCMKTS:TRMLF
Stock Price: $15.95 (-$0.53)
Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $26.21 (64.4% Upside)
Tourmaline Oil Corp. acquires, explores for, develops, and produces oil and natural gas properties in the Western Canadian Sedimentary Basin. It holds interests in properties located in the Alberta Deep Basin, Northeast British Columbia Montney, and the Peace River High Triassic oil complex. The company was founded in 2008 and is headquartered in Calgary, Canada.
AltaGas logo

#17 - AltaGas

OTCMKTS:ATGFF
Stock Price: $15.79 (-$0.16)
Consensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $22.21 (40.7% Upside)
AltaGas Ltd. operates as a diversified energy infrastructure company in North America. The company operates through three segments: Utilities, Midstream, and Power. The Utilities segment owns and operates regulated natural gas distribution utilities in Michigan, Alaska, the District of Columbia, Maryland, and Virginia; and two regulated natural gas storage utilities in the United States serving approximately 1.7 million customers. This segment also provides interstate natural gas transportation and storage services. It serves homes and businesses. The Midstream segment engages in the natural gas gathering and processing; natural gas liquids (NGL) extraction and fractionation, transmission, and storage; natural gas and NGL marketing; and gas retail marketing activities. This segment owns approximately 1.4 billion cubic feet per day (Bcf/d) of natural gas extraction processing capacity and holds interests in regulated pipelines in the Marcellus/Utica gas formation in the northeastern United States. It serves residential, commercial, and industrial customers primarily in the Western Canada Sedimentary Basin. The Power segment is involved in the generation and sale of electricity; and provision of energy storage and retail power marketing, and ancillary services in Alberta, California, and Colorado. It has 710 megawatt of operational gross capacity from natural gas-fired, biomass, solar, and distributed energy. This segment serves residential, commercial, and industrial users. AltaGas Ltd. was founded in 1994 and is headquartered in Calgary, Canada.
Brookfield Asset Management logo

#18 - Brookfield Asset Management

NYSE:BAM
Stock Price: $38.81 (-$0.44)
PE Ratio: -1,058.07
Market Cap: $61.16 billion
Dividend Yield: 1.22 %
Consensus Rating: Buy (9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $44.50 (14.7% Upside)
Brookfield Asset Management is a leading global alternative asset manager and one of the largest investors in real assets. Our investment focus is on real estate, renewable power, infrastructure and private equity assets. Our objective is to generate attractive long-term risk-adjusted returns for the benefit of our clients and shareholders. We manage a range of public and private investment products and services for institutional and retail clients. We earn asset management income for doing so and align our interests with our clients by investing alongside them. We have an exceptionally strong balance sheet, with over $30 billion of capital invested, primarily in our four listed partnerships: Brookfield Property Partners, Brookfield Infrastructure Partners, Brookfield Renewable Partners and Brookfield Business Partners. This access to large-scale capital enables us to make investments in sizeable, premier assets across geographies and asset classes that few managers are able to do. We create value for BAM shareholders in the following ways: As an asset manager Â- by investing both our own capital and that of our investors Â- this enables us to increase the scale of our operations, and enhances our financial returns through base management fees and performance-based income; as an investor and capital allocator Â- we strive to invest at attractive valuations, particularly in value-oriented situations that create opportunities for superior valuation gains and cash flow returns, or by monetizing assets at appropriate times to realize value; and as an owner-operator Â- we constantly work to increase the value of the assets within our operating businesses and the cash flows they produce through our operating expertise, development capabilities and effective financing.
Health Catalyst logo

#19 - Health Catalyst

NASDAQ:HCAT
Stock Price: $48.14 (+$0.55)
PE Ratio: -21.40
Market Cap: $2.05 billion
Consensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $42.54 (-11.6% Upside)
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was founded in 2008 and is headquartered in Salt Lake City, Utah.
Viking Therapeutics logo

#20 - Viking Therapeutics

NASDAQ:VKTX
Stock Price: $6.79 (-$0.07)
PE Ratio: -13.86
Market Cap: $495.34 million
Consensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.56 (143.8% Upside)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.